| Literature DB >> 21422694 |
Yasushi Matsuyama1, Takao Nagashima, Kyoko Honne, Yasuyuki Kamata, Masahiro Iwamoto, Hitoaki Okazaki, Kazuya Sato, Keiya Ozawa, Seiji Minota.
Abstract
A 63-year-old woman receiving tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) was found to have smoldering IgA-kappa type multiple myeloma (MM). Retrospective examination of stored serum samples revealed a steady increase of serum IgA levels after the start of TNF inhibitor therapy. The patient's articular symptoms showed marked exacerbation when TNF inhibitors were discontinued because of fear of worsening the MM. Tocilizumab improved RA symptoms dramatically and stabilized serum IgA levels for 13 months after a transient steep rise. This case suggests that tocilizumab can be used safely in patients with inflammatory disorders with coexisting MM.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21422694 DOI： 10.2169/internalmedicine.50.4636
Source DB: PubMed Journal: Intern Med ISSN： 0918-2918 Impact factor: 1.271